Equity Profile

TECH

Bio-Techne Corporation

Health CareLife Sciences Tools & Services$8.1B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2026Pre-Market9:00 AM EDT

Company Snapshot

Bio-Techne Corporation operates in the health care sector, focusing on life sciences tools and services. The company is important for its role in providing essential products and technologies that support research and clinical diagnostics, which are critical in advancing health care solutions.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, exceeding expectations by 11.11%. However, the stock fell 16.36% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Bio-Techne's upcoming earnings are mixed, with investors eager to see if the company can continue its streak of beating EPS estimates.

Bull Case

If Bio-Techne maintains or exceeds its previous EPS performance, it could signal strong operational efficiency and market demand, leading to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue growth, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given the company's history of beating EPS estimates, this number will be crucial in determining investor sentiment and stock movement.

How is revenue growth trending compared to previous quarters?

Investors will closely watch revenue growth as it indicates the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Bio-Techne's ability to innovate and capture market share, especially in emerging areas of life sciences.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational management.

Options pricing suggests a larger potential move than historical averages, reflecting investor uncertainty.

Recent insider activity shows no significant selling, which could imply confidence in the company's future performance.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Techne can sustain its growth trajectory amid increasing competition and market pressures.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong operational performance and could lead to positive market sentiment.

Bear Confirmed If

An EPS below $0.50 would signal potential issues in profitability and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 7.46%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but lack strong commentary, the stock may experience a muted reaction as investors await further clarity.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 1.90%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the life sciences sector.
2Details on customer demand trends and market share changes.
3Insights into cost management and gross margin performance.
4Management's outlook on future revenue growth and market conditions.
5Any commentary on competitive pressures and how the company plans to address them.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and increase sales, which is vital for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TECH Q4-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+20.74%

Avg Stock Reaction

-2.11%

Last Quarter Recap

In Q3-2026, Bio-Techne reported an EPS of $0.53, exceeding expectations by 11.11%. However, the stock fell 16.36% the following day, indicating market concerns despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Bio-Techne's upcoming earnings are mixed, with investors eager to see if the company can continue its streak of beating EPS estimates.

Bull Case

If Bio-Techne maintains or exceeds its previous EPS performance, it could signal strong operational efficiency and market demand, leading to positive investor sentiment.

Bear Case

Conversely, if the company fails to meet expectations or shows signs of declining revenue growth, it could lead to a significant drop in stock price, as seen in previous quarters.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q4-2026?

Given the company's history of beating EPS estimates, this number will be crucial in determining investor sentiment and stock movement.

How is revenue growth trending compared to previous quarters?

Investors will closely watch revenue growth as it indicates the company's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Bio-Techne's ability to innovate and capture market share, especially in emerging areas of life sciences.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational management.

Options pricing suggests a larger potential move than historical averages, reflecting investor uncertainty.

Recent insider activity shows no significant selling, which could imply confidence in the company's future performance.

Key Risk

If revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Bio-Techne can sustain its growth trajectory amid increasing competition and market pressures.

Bull Confirmed If

An EPS of $0.55 or higher would confirm strong operational performance and could lead to positive market sentiment.

Bear Confirmed If

An EPS below $0.50 would signal potential issues in profitability and could lead to a negative market reaction.

Pre-Earnings Positioning

Options Market

Implied Move

±30.67%

Historical Avg

±7.0%

Pricing rich

The options market is pricing in a significant potential movement in the stock price, indicating heightened uncertainty or anticipation surrounding the earnings report.

Options are pricing ±30.7% while TECH has averaged ±7.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

80.0%

Calls (15K)P/C Ratio: 0.01Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Techne beats expectations, history suggests a potential stock increase of around 7.46%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but lack strong commentary, the stock may experience a muted reaction as investors await further clarity.

Miss

If the company misses EPS expectations, history suggests a potential decline of around 1.90%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

0 buys·3 sells

Members

House only

Est. Notional

$3,003.00–$45,000.00

disclosed dollar ranges

Most Active Members

D-MDApril McClain DelaneyRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or innovations in the life sciences sector.
2Details on customer demand trends and market share changes.
3Insights into cost management and gross margin performance.
4Management's outlook on future revenue growth and market conditions.
5Any commentary on competitive pressures and how the company plans to address them.